Changes in metabolic syndrome Status after initiation of antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 68, Issue 1, 2015, Pages 73-80

  Krishnan, Supriya ^a   Schouten, Jeffrey T ^b   Atkinson, Benjamin ^c   Brown, Todd T ^d   Wohl, David A ^e   McComsey, Grace A ^f   Glesby, Marshall J ^g   Shikuma, Cecilia ^h   Haubrich, Richard ⁱ   Jacobson, Denise L ^d  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF HAWAII   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ART; Body mass index; Changes; HIV; Metabolic syndrome; Prevalence

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MCNEMAR TEST; METABOLIC SYNDROME X; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; COMPLICATION; HIV INFECTIONS; PATHOPHYSIOLOGY;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; METABOLIC SYNDROME X;

EID: 84919360241     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000397     Document Type: Article

References (29)

1. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-1645
2. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes. 2010;2:180-193
3. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376:49-62
4. Fichtenbaum CJ. Metabolic abnormalities associated with HIV infection and antiretroviral therapy. Curr Infect Dis Rep. 2009;11:84-92
5. Wohl DA, Brown TT. Management of morphologic changes associated with antiretroviral use in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;49(suppl 2):S93-S100
6. Krishnan S, Schouten JT, Atkinson B, et al. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr. 2012;61:381-389
7. Smurzynski M, Collier AC, Koletar SL, et al. AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics. HIV Clin Trials. 2008;9:269-282
8. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-1861
9. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-2106
10. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009; 361:2230-2240
11. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978-2982
12. Worm SW, Lundgren JD. The metabolic syndrome in HIV. Best Pract Res Clin Endocrinol Metab. 2011;25:479-486
13. Duro M, Sarmento-Castro R, Almeida C, et al. Lipid profile changes by high activity anti-retroviral therapy. Clin Biochem. 2013;46:740-744
14. Mooradian AD, Haas MJ, Wehmeier KR, et al. Obesity-related changes in high-density lipoprotein metabolism. Obesity (Silver Spring). 2008;16: 1152-1160
15. Wang H, Peng DQ. New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids Health Dis. 2011;10:176
16. Amorosa V, Synnestvedt M, Gross R, et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr. 2005;39:557-561
17. Mandina Ndona M, Longo-Mbenza B, Wumba R, et al. Nadir CD4+, religion, antiretroviral therapy, incidence of type 2 diabetes mellitus, and increasing rates of obesity among black Africans with HIV disease. Int J Gen Med. 2012;5:983-990
18. Malaza A, Mossong J, Barnighausen T, et al. Hypertension and obesity in adults living in a high HIV prevalence rural area in South Africa. PLoS One. 2012;7:e47761
19. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53: 323-332
20. Wilson PW, DAgostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867-1872
21. Nguyen NT, Magno CP, Lane KT, et al. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg. 2008;207:928-934
22. Crum-Cianflone N, Roediger MP, Eberly L, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One. 2010;5:e10106
23. Lazzaretti RK, Kuhmmer R, Sprinz E, et al. Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals: a randomized trial. J Am Coll Cardiol. 2012;59:979-988
24. Haffner SM. Abdominal adiposity and cardiometabolic risk: do we have all the answers? Am J Med. 2007;120:S10-S16; discussion S6-S7
25. Krishnan SBR, Rodriguez B, Hunt PW, et al. Correlates of inflammatory markers after one year of suppressive antiretroviral treatment. Paper presented at: 21th Conference on Retroviruses and Opportunistic Infections (CROI); 2014; Boston, MA.
26. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDSdefining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210:1248-1259
27. Srinivasa S, Grinspoon SK. Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients. Eur J Endocrinol. 2014; 170:R185-R202
28. Piconi S, Parisotto S, Rizzardini G, et al. Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviralnaive or treated individuals. AIDS. 2013;27:381-389
29. Parrinello CM, Landay AL, Hodis HN, et al. Treatment-related changes in serum lipids and inflammation: clinical relevance remains unclear. Analyses from the Womens Interagency HIV study. AIDS. 2013;27: 1516-1519.